Chinese vaccine products go global: vaccine development and quality control

References

• Pang X, Zhu Z, Xu F, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA 2003;290(24):3215-21
   PubMed Web of Science ®Google Scholar
• Cohen J, Enserink M. Infectious diseases. As swine flu circles globe, scientists grapple with basic questions. Science 2009;324(5927):572-3
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368(20):1888-97
   PubMed Web of Science ®Google Scholar
• Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa - clinical manifestations and management. N Engl J Med 2014;371(22):2054-7
   PubMed Web of Science ®Google Scholar
• Liang X, Wu Z. Implementation of EPI for 30 years to protect hundreds of millions of people’s health. Chin J Prevent Med 2008;42(Suppl):4-6
   Google Scholar
• Zheng J, Zhou Y, Wang H, Liang X. The role of the China Experts Advisory Committee on Immunization Program. Vaccine 2010;28(Suppl 1):A84-7
   Google Scholar
• Wang L, Wang Y, Jin S, et al. Emergence and control of infectious diseases in China. Lancet 2008;372(9649):1598-605
   PubMed Web of Science ®Google Scholar
• Programmes and projects/Immunization surveillance, assessment and monitoring/Vaccine-preventable diseases. World Health Organization. Geneva. Available from: www.who.int/immunization_monitoring/diseases/pertussis/en/index.html [Last accessed 22 September 2014]
   Google Scholar
• National Committee for the Certification of Poliomyelitis Eradication in China: Documentation for the Certification of Poliomyelitis Eradication, the People’s Republic of China. Document by Ministry of Health. 2000
   Google Scholar
• World Health Organization. Geneva Available from: http://apps.who.int/gho/data/view.main.680?lang=en [Last accessed 20 September 2014]
   Google Scholar
• Elmgren L, Li X, Wilson C, et al. A global regulatory science agenda for vaccines. Vaccine 2013;31(Suppl 2):B163-75
   PubMedGoogle Scholar
• Li H. The major achievements of biological products in China. Chin Med J (Engl) 2000;113(10):942-7
   PubMed Web of Science ®Google Scholar
• Li HM, Yu Y, Ao J. Antigenicity and immunogenicity of JE strains isolated from different regions. In: selected works of China symposium on infectious diseases. People’s Health Press; Beijing: 1959
   Google Scholar
• Aihara S, Rao CM, Yu YX, et al. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes 1991;5(2):95-109
   PubMed Web of Science ®Google Scholar
• Wang SG YH, Den YJ. Studies on the production of SA 14-2 Japanese encephalitis live vaccine. Chin J Virol 1990;6:38-43
   Google Scholar
• Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997;176(5):1366-9
   PubMed Web of Science ®Google Scholar
• Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996;347(9015):1583-6
   PubMed Web of Science ®Google Scholar
• Jia L, Wang Z, Yu Y. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses. Chin Med J (Engl) 2003;116(6):941-3
   PubMed Web of Science ®Google Scholar
• Sohn YM, Park MS, Rho HO, et al. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 1999;17(18):2259-64
   PubMed Web of Science ®Google Scholar
• Mao JS. Development of live, attenuated hepatitis A vaccine (H2-strain). Vaccine 1990;8(6):523-4
   PubMed Web of Science ®Google Scholar
• Mao JS, Dong DX, Zhang HY, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989;159(4):621-4
   PubMed Web of Science ®Google Scholar
• Zou Q, Tong W, Mao X, et al. Oral recombinant helicobacter pylori vaccine and preparing method thereof; United States Chongqing Kang Wei Biotechnology Co. Ltd. (Chongquing City, CN) 20110171315. Available from: www.freepatentsonline.com/y2011/0171315.html [Last accessed 26 September 2014]
   Google Scholar
• Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376(9744):895-902
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012;205(2):237-43
   PubMed Web of Science ®Google Scholar
• Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009;361(26):2507-17
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin TY, Hsu KH, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999;354(9191):1682-6
   PubMed Web of Science ®Google Scholar
• Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011;6(9):e25662
   PubMed Web of Science ®Google Scholar
• Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010;363(25):2416-23
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014;370(9):829-37
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014;370(9):818-28
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013;381(9871):1037-45
   PubMed Web of Science ®Google Scholar
• China enters the global vaccine market. World Health Organization. Geneva. 2014. Available from: www.who.int/bulletin/volumes/92/9/14-020914.pdf [Last accessed 10 August 2014]
   Google Scholar
• The State Council of the People’s Republic of China.Vaccine supply system construction plan. 2011
   Google Scholar
• Tracking progress towards global polio eradication, 2010-2011. Wkly Epidemiol Rec 2012;87(16):153-60
   PubMedGoogle Scholar
• Ma C, Hao L, Zhang Y, et al. Monitoring progress towards the elimination of measles in China: an analysis of measles surveillance data. Bull World Health Organ 2014;92(5):340-7
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination. Vaccine 2013;31(Suppl 9):J21-8
   PubMed Web of Science ®Google Scholar
• Fan Z, Guan H, Luo S, et al. [Validation on the elimination of neonatal tetanus programs through Lot Quality Assurance-Cluster Sample Survey in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2014;35(2):163-6
   PubMedGoogle Scholar
• Shen J, Kang J, Shi Y, et al. Lessons learned from the Wenchuan earthquake. J Evid Based Med 2012;5(2):75-88
   PubMedGoogle Scholar
• Zhang L, Liu X, Li Y, et al. Emergency medical rescue efforts after a major earthquake: lessons from the 2008 Wenchuan earthquake. Lancet 2012;379(9818):853-61
   PubMed Web of Science ®Google Scholar
• China Pharmacopoeia Committee. 2010 edition Chinese Pharmacopoeia. 3 volumes China Medico-Pharmaceutical Science & Technology Publishing House; Beijing, China: 2010
   Google Scholar
• He P, Hong X, Guo Z, et al. Comparison of standards and methods for the quality control of hepatitis A and hepatitis B vaccines in Chinese Pharmacorpoeia, European Pharmacopoeia and WHO draft. Chin J Pharm Anal 2011;31(10):1996-9
   Google Scholar
• Guidelines for independent lot release of vaccines by regulartory authorities. Adopted by the 61th meeting of WHO ECBS. World Health Organization. Geneva. 2010. Available from: http:/www.who.int/biologicals/guidelines_for_lot_release_after_ecbs_27.1.2011.pdf [Last accessed 3 August 2014]
   Google Scholar
• Jia L, Yang R, Dong G. Study on improvement of national lot release regulations on biological products. Chin Pharmaceut Affairs 2010;24(6):523-30
   Google Scholar
• Hou J, Li F. European commission batch release regulation comparing with chinese and some main points to be considered. Chin Pharmaceut Affairs 2007;21(8):546-8
   Google Scholar
• Wang L, Zhang L, Hou Q, et al. Retrospective analysis of lot release and potency assays of pertussis vaccines in China. Chin J Biologicals 2012;25(8):1072-4
   Google Scholar
• Liu X, Zhang J, Jia L, et al. Application of trend analysis in quality control of Japanese Encephalitis attenuated live vaccines. Chin J Biologicals 2012;25(11):1562-4
   Google Scholar
• Chen Z, Qiu P, ZHAO H, et al. Sumarry of lot release of Varicellar-zoster virus attenuated live vaccines in China. Chin J Biologicals 2013;26(8):1197-20
   Google Scholar
• Kong L. Comprehensive promotion of drug electronic supervision code. China Licensed Pharmacist 2010;7(6):39-41
   Google Scholar
• Li L, Yan J, Shao R. Comparison of system structure of newly revised Chinese GMP in 2010 with foreign typical GMPs. Chin J N Drugs 2014;23(5):505-9
   Google Scholar
• Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ 2003;52(1):1-24
   PubMedGoogle Scholar
• Wu W, Liu D, Wu B, et al. Analysis on the surveillance of adverse events following immunization in China,2007-2008. Chin J Vacc Immun 2009;15(6):481-90
   Google Scholar
• Chen C, Zhou J, Li D, et al. Surveillance of suspected adverse events following immunization during booster immunizations with live attenuated measles vaccine and routine immunization with measles-containing vaccines in Jilin Province. Chin J Biological 2012;25(1):95-8
   Google Scholar
• Hao Z, Zhong Y, Ao K. Study on adverse events following immunization of the measles attenuated live vaccine for supplementary immunization activities in qinghai province in 2010. Chin J Vacc Immun 2012;18(1):51-3
   Google Scholar
• Wu J, Li W, Wang HQ, et al. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010;202(5):675-80
   PubMed Web of Science ®Google Scholar
• Li C, Shao M, Cui X, et al. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 2010;38(2):284-9
   PubMed Web of Science ®Google Scholar
• Mao Q, Li N, Yu X, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012;157(1):37-41
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011;29(52):9668-74
   PubMed Web of Science ®Google Scholar